Cyclerion Therapeutics (NASDAQ:KRSA) Stock Price Breaks Above 50 Day Moving Average – Time to Sell?

Cyclerion Therapeutics, Inc. (NASDAQ:KRSA – Get Free Report)’s share price passed above its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $32.09 and traded as high as $34.18. Cyclerion Therapeutics shares last traded at $32.68, with a volume of 319,840 shares changing hands.

Wall Street Analysts Forecast Growth

KRSA has been the subject of a number of research reports. Guggenheim started coverage on shares of Cyclerion Therapeutics in a research report on Monday, September 28th. They set a “buy” rating and a $70.00 target price for the company. Wells Fargo & Company assumed coverage on shares of Cyclerion Therapeutics in a research note on Friday, November 13th. They set an “overweight” rating and a $44.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cyclerion Therapeutics in a report on Friday, July 24th. UBS Group assumed coverage on shares of Cyclerion Therapeutics in a research note on Friday, September 11th. They issued a “buy” rating and a $55.00 price objective for the company. Finally, Wedbush initiated coverage on shares of Cyclerion Therapeutics in a report on Monday, October 5th. They set an “outperform” rating and a $44.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $51.20.

Get Our Latest Stock Report on KRSA

Cyclerion Therapeutics Stock Performance

The company has a fifty day simple moving average of $32.12.

Cyclerion Therapeutics (NASDAQ:KRSA – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($3.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($50.40) by $47.21. As a group, equities analysts predict that Cyclerion Therapeutics, Inc. will post -5.35 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Cyclerion Therapeutics

Institutional investors have recently made changes to their positions in the stock. ADAR1 Capital Management LLC purchased a new stake in Cyclerion Therapeutics during the second quarter valued at about $1,013,000. Braidwell LP purchased a new position in shares of Cyclerion Therapeutics in the 2nd quarter worth about $532,000. Finally, BlackRock Inc. purchased a new position in shares of Cyclerion Therapeutics in the 2nd quarter worth about $57,000. Institutional investors own 75.62% of the company’s stock.

Cyclerion Therapeutics Company Profile

(Get Free Report)

Cyclerion Therapeutics was a clinical-stage biotechnology company focused on developing medicines for serious disorders of the central nervous system. The company originated as a spinout from Ironwood Pharmaceuticals in 2019 and was based in Cambridge, Massachusetts. Its research centered on small-molecule drugs that stimulate soluble guanylate cyclase, an enzyme involved in cellular signaling. Cyclerion’s development portfolio included zagociguat, an investigational, brain-penetrant candidate studied for conditions including cognitive impairment associated with Alzheimer’s disease and other neurological disorders.

Further Reading

Receive News & Ratings for Cyclerion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclerion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.